214 related articles for article (PubMed ID: 12727818)
1. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
Wang LH; Yang XY; Zhang X; Mihalic K; Xiao W; Farrar WL
Cancer Res; 2003 May; 63(9):2046-51. PubMed ID: 12727818
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor decoy against promoter C of estrogen receptor alpha gene induces a functional ER alpha protein in breast cancer cells.
Lambertini E; Penolazzi L; Magaldi S; Giordano S; Senno LD; Piva R
Breast Cancer Res Treat; 2005 Jul; 92(2):125-32. PubMed ID: 15986121
[TBL] [Abstract][Full Text] [Related]
3. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
4. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
5. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
6. A c-fos/Estrogen receptor fusion protein promotes cell cycle progression and proliferation of human cancer cell lines.
Crowe DL; Brown TN; Kim R; Smith SM; Lee MK
Mol Cell Biol Res Commun; 2000 Apr; 3(4):243-8. PubMed ID: 10891399
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
8. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
[TBL] [Abstract][Full Text] [Related]
10. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells.
Márquez DC; Pietras RJ
Oncogene; 2001 Sep; 20(39):5420-30. PubMed ID: 11571639
[TBL] [Abstract][Full Text] [Related]
11. 17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
Bonapace IM; Addeo R; Altucci L; Cicatiello L; Bifulco M; Laezza C; Salzano S; Sica V; Bresciani F; Weisz A
Oncogene; 1996 Feb; 12(4):753-63. PubMed ID: 8632897
[TBL] [Abstract][Full Text] [Related]
12. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
13. Recovery of cellular E-cadherin precedes replenishment of estrogen receptor and estrogen-dependent proliferation of breast cancer cells rescued from a death stimulus.
Malaguti C; Rossini GP
J Cell Physiol; 2002 Aug; 192(2):171-81. PubMed ID: 12115723
[TBL] [Abstract][Full Text] [Related]
14. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
15. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
16. Osteoblastic differentiation induced by transcription factor decoy against estrogen receptor alpha gene.
Lambertini E; Penolazzi L; Aguiari G; del Senno L; Pezzetti F; Sollazzo V; Piva R
Biochem Biophys Res Commun; 2002 Apr; 292(3):761-70. PubMed ID: 11922631
[TBL] [Abstract][Full Text] [Related]
17. ERbeta sensitizes breast cancer cells to retinoic acid: evidence of transcriptional crosstalk.
Rousseau C; Nichol JN; Pettersson F; Couture MC; Miller WH
Mol Cancer Res; 2004 Sep; 2(9):523-31. PubMed ID: 15383631
[TBL] [Abstract][Full Text] [Related]
18. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation.
Geraldes P; Sirois MG; Tanguay JF
Circ Res; 2003 Sep; 93(5):399-405. PubMed ID: 12893737
[TBL] [Abstract][Full Text] [Related]
19. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.
Chai Y; Chipitsyna G; Cui J; Liao B; Liu S; Aysola K; Yezdani M; Reddy ES; Rao VN
Oncogene; 2001 Mar; 20(11):1357-67. PubMed ID: 11313879
[TBL] [Abstract][Full Text] [Related]
20. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
